These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1031 related items for PubMed ID: 17470865

  • 1. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS.
    J Clin Oncol; 2007 May 01; 25(13):1753-9. PubMed ID: 17470865
    [Abstract] [Full Text] [Related]

  • 2. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA.
    AJR Am J Roentgenol; 2004 Dec 01; 183(6):1619-28. PubMed ID: 15547201
    [Abstract] [Full Text] [Related]

  • 3. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J.
    Oncology; 2005 Dec 01; 69(4):326-32. PubMed ID: 16293972
    [Abstract] [Full Text] [Related]

  • 4. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.
    Rev Esp Med Nucl; 2008 Dec 01; 27(3):168-75. PubMed ID: 18570858
    [Abstract] [Full Text] [Related]

  • 5. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.
    J Clin Oncol; 2009 Jan 20; 27(3):439-45. PubMed ID: 19064982
    [Abstract] [Full Text] [Related]

  • 6. Response evaluation of gastrointestinal stromal tumors.
    Choi H.
    Oncologist; 2008 Jan 20; 13 Suppl 2():4-7. PubMed ID: 18434631
    [Abstract] [Full Text] [Related]

  • 7. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD.
    AJR Am J Roentgenol; 2007 Dec 20; 189(6):W324-30. PubMed ID: 18029844
    [Abstract] [Full Text] [Related]

  • 8. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D.
    J Nucl Med; 2004 Jan 20; 45(1):17-21. PubMed ID: 14734662
    [Abstract] [Full Text] [Related]

  • 9. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E, García-Garzón JR, Ponce-López A, Soler-Peter M, Fuertes-Cabero S, Moragas-Solanes M, Riera-Gil E, Carrió-Gasset I, Lomeña-Caballero F.
    Rev Esp Enferm Dig; 2012 Jul 20; 104(7):360-6. PubMed ID: 22849497
    [Abstract] [Full Text] [Related]

  • 10. The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
    Van den Abbeele AD.
    Oncologist; 2008 Jul 20; 13 Suppl 2():8-13. PubMed ID: 18434632
    [Abstract] [Full Text] [Related]

  • 11. We should desist using RECIST, at least in GIST.
    Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C.
    J Clin Oncol; 2007 May 01; 25(13):1760-4. PubMed ID: 17470866
    [Abstract] [Full Text] [Related]

  • 12. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S, Sevinc A, Kalender ME, Camci C.
    World J Gastroenterol; 2007 Apr 21; 13(15):2261-2. PubMed ID: 17465516
    [Abstract] [Full Text] [Related]

  • 13. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H.
    Anticancer Res; 2005 Apr 21; 25(6C):4591-4. PubMed ID: 16334147
    [Abstract] [Full Text] [Related]

  • 14. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.
    J Nucl Med; 2012 Apr 21; 53(4):567-74. PubMed ID: 22381410
    [Abstract] [Full Text] [Related]

  • 15. PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy.
    Eslamy HK, Quon A.
    Clin Nucl Med; 2008 Dec 21; 33(12):864-5. PubMed ID: 19033789
    [Abstract] [Full Text] [Related]

  • 16. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA, Nair N.
    Clin Nucl Med; 2008 Mar 21; 33(3):213-4. PubMed ID: 18287851
    [No Abstract] [Full Text] [Related]

  • 17. Esophageal gastrointestinal stromal tumor: report of 7 patients.
    Shinagare AB, Zukotynski KA, Krajewski KM, Jagannathan JP, Butrynski J, Hornick JL, Ramaiya NH.
    Cancer Imaging; 2012 Apr 27; 12(1):100-8. PubMed ID: 22542728
    [Abstract] [Full Text] [Related]

  • 18. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [Abstract] [Full Text] [Related]

  • 19. The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.
    Dietrich C, Hartung E, Ignee A.
    Ultraschall Med; 2008 Dec 15; 29 Suppl 5():276-7. PubMed ID: 19177288
    [No Abstract] [Full Text] [Related]

  • 20. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
    Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F.
    Q J Nucl Med Mol Imaging; 2011 Dec 15; 55(6):680-7. PubMed ID: 21150863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.